Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT01563978. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
OSKIRA-ABPM: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients With Rheumatoid Arthritis
Study identification
- NCT ID
- NCT01563978
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 266 participants
Conditions and interventions
Conditions
Interventions
- fostamatinib Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2012
- Primary completion
- Dec 31, 2012
- Completion
- Dec 31, 2012
- Last update posted
- May 7, 2014
2012 – 2013
United States locations
- U.S. sites
- 30
- U.S. states
- 17
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Huntsville | Alabama | — | — |
| Research Site | Huntington Beach | California | — | — |
| Research Site | Santa Maria | California | — | — |
| Research Site | Trumbull | Connecticut | — | — |
| Research Site | Boca Raton | Florida | — | — |
| Research Site | Brandon | Florida | — | — |
| Research Site | Orlando | Florida | — | — |
| Research Site | Tampa | Florida | — | — |
| Research Site | Venice | Florida | — | — |
| Research Site | Decatur | Georgia | — | — |
| Research Site | South Bend | Indiana | — | — |
| Research Site | Cumberland | Maryland | — | — |
| Research Site | Frederick | Maryland | — | — |
| Research Site | Hagerstown | Maryland | — | — |
| Research Site | Florissant | Missouri | — | — |
| Research Site | Richmond Heights | Missouri | — | — |
| Research Site | Freehold | New Jersey | — | — |
| Research Site | Albuquerque | New Mexico | — | — |
| Research Site | Brooklyn | New York | — | — |
| Research Site | Charlotte | North Carolina | — | — |
| Research Site | Greensboro | North Carolina | — | — |
| Research Site | Lake Oswego | Oregon | — | — |
| Research Site | Duncansville | Pennsylvania | — | — |
| Research Site | Memphis | Tennessee | — | — |
| Research Site | Austin | Texas | — | — |
| Research Site | Dallas | Texas | — | — |
| Research Site | Houston | Texas | — | — |
| Research Site | Lubbock | Texas | — | — |
| Research Site | Nassau Bay | Texas | — | — |
| Research Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01563978, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2014 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01563978 live on ClinicalTrials.gov.